# OnCo record nct05514054 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct05514054/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct05514054", "NCT05514054" ;
  schema:name "A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer"@en ;
  schema:alternateName "EMBER-4"@en ;
  schema:description "A phase 3 trial of Imlunestrant, Tamoxifen and Exemestane in advanced solid tumours, run by Eli Lilly and Company, active and no longer recruiting."@en ;
  schema:url <https://onco.cc/trials/nct05514054/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT05514054> ;
  onco:status "active" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "3" ;
  schema:startDate "2022-10-04" ;
  onco:cancers <https://onco.cc/cancers/metastatic-cancer/> ;
  onco:technologies <https://onco.cc/technologies/endocrine-therapy/> ;
  onco:drugs <https://onco.cc/drugs/imlunestrant/>, <https://onco.cc/drugs/tamoxifen/>, <https://onco.cc/drugs/exemestane/> ;
  onco:companies <https://onco.cc/companies/eli-lilly/> .